Late cardiotoxicity after treatment for a malignant bone tumor

QT Dispersion Correlates with Systolic Rather than Diastolic Parameters in Patients Receiving Anthracycline Treatment

“…Anthracycline treatment causes non-specific electrocardiographic change, such as ST-T change, prolongation of QT interval, decreased QRS voltage, and various arrhythmias (2,9,10). Furthermore, recent reports show that anthracycline treatment induces increased QT dispersion, which could be an early marker of anthracycline-induced cardiotoxicity (11)(12)(13).…”

Cardiopathie aux anthracyclines

“…Après exposition aux anthracyclines, les adultes développent essentiellement une cardiopathie dilatée chronique [33]. Les enfants ont pour leur part une forme dilatée en fin de traitement qui peut progresser vers une forme restrictive [21,32,34,35]. Cette évolution pourrait faire suite à la majoration de la post-charge ventriculaire gauche secondaire à l'amincissement de l'épaisseur pariétale et à la réduction de la masse ventriculaire gauche alors même que la pression artérielle est normale voire diminuée [21].…”

The Monitoring of Potential Long-Term Complications in Treated Adult Cancer Patients

“…25 Depending on presentation, patients developing cardiac symptoms after anthracycline chemotherapy should be investigated with radionuclide angiography, ultrasound studies and possible endomyocardial biopsy. 25,27 In patients with suspected cardiac arrhythmia, 24-hour ambulatory EKG monitoring is advisable. A left ventricular ejection fraction of less than 35%, or a 15% decrease from base line results, is strongly suggestive of high risk or cardiac decompensation.…”

“…25 Other studies have indicated that determination of the left ventricular posterior wall thickness index may be a good marker for potential long-term toxicity. 27 Congestive failure secondary to chronic measures such as diuretics, ACE inhibition and digoxin therapy. However, the ultimate prognosis remains guarded.…”